Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 54 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Leuprorelin acetate in addition to tamoxifen or an aromatase inhibitor for ER-positive early stage breast cancer in premenopausal women - adjuvant	Leuprorelin acetate (Prostap DCS; Prostap Depot) , Tamoxifen	Breast cancer	Breast Cancer	2018	View \| Download
Neoadjuvant atezolizumab with chemotherapy followed by adjuvant atezolizumab for treating triple-negative breast cancer	Atezolizumab (Tecentriq; MPDL3280A) , Chemotherapy	Breast cancer	Breast Cancer	2022	View \| Download
Olaparib for BRCA mutated and high risk HER2 negative breast cancer - adjuvant therapy	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Breast cancer	Breast Cancer	2020	View \| Download
Paclitaxel with Encequidar for advanced breast cancer	Encequidar (HM-30181) , Paclitaxel (Taxol; paclitaxel albumin)	Breast cancer	Breast Cancer	2022	View \| Download
Palbociclib for breast cancer - post neoadjuvant therapy	Palbociclib (Ibrance; PD-0332991)	Breast cancer	Breast Cancer	2020	View \| Download
Palbociclib with trastuzumab with or without pertuzumab and endocrine therapy for HR+/HER2+ metastatic breast cancer	Palbociclib (Ibrance; PD-0332991) , Trastuzumab (Herceptin; RG-597)	Breast cancer	Breast Cancer	2023	View \| Download
Pembrolizumab (Keytruda) for triple negative breast cancer	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2017	View \| Download
Pembrolizumab in addition to Chemotherapy for Locally Advanced, Non-Metastatic Triple Negative Breast Cancer – neoadjuvant, first line	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2018	View \| Download
Pembrolizumab in addition to chemotherapy for locally recurrent, inoperable or metastatic triple-negative breast cancer - first line	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2018	View \| Download
Pembrolizumab in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for early-strage breast cancer	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2021	View \| Download